Non-Invasive Genomic Monitoring to Improve Transplant Outcomes
Transplant Genomics aims to improve transplant outcomes through molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes, and enable optimization of therapy.
~35% of patients receive a surveillance biopsy in the first year
≥75% of patients who have surveillance biopsies show normal histology and the vast majority could have been spared an invasive procedure if tested with TruGraf®
≥20% of patients show subclinical acute rejection